ICT
MCID: CRC014
MIFTS: 48

Carcinoid Tumors, Intestinal (ICT)

Categories: Cancer diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Carcinoid Tumors, Intestinal

MalaCards integrated aliases for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 57 12 5
Gastrointestinal Carcinoid Tumor 73 53 71
Argentaffinoma 73 71
Carcinoid 73 53
Carcinoid Tumor No Icd-O Subtype 71
Malignant Carcinoid Syndrome 71
Tumor, Carcinoid, Intestinal 38
Carcinoid Tumor of Intestine 71
Intestinal Carcinoid Tumor 73
Carcinoid Tumor 71
Ict 73

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

OMIM® 57 114900
MeSH 43 D002276
MedGen 40 C0349535
UMLS 71 C0007095 C0024586 C0220620 more

Summaries for Carcinoid Tumors, Intestinal

UniProtKB/Swiss-Prot: 73 A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary: Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to goblet cell carcinoid and appendix carcinoid tumor. An important gene associated with Carcinoid Tumors, Intestinal is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways is Neuroscience. The drugs Histamine and Cyproheptadine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, lung and appendix, and related phenotypes are intestinal carcinoid and nervous system

More information from OMIM: 114900

Related Diseases for Carcinoid Tumors, Intestinal

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1286)
# Related Disease Score Top Affiliating Genes
1 goblet cell carcinoid 32.7 ENO2 CHGA
2 appendix carcinoid tumor 31.9 SYP ENO2 CHGA
3 appendix adenocarcinoma 31.7 SYP CHGA
4 pulmonary blastoma 31.3 SYP NKX2-1 CHGA
5 rectum neuroendocrine neoplasm 31.2 SYP SST GAST
6 gastritis 30.9 SST GAST CHGA
7 mature teratoma 30.8 SYP ENO2
8 serotonin syndrome 30.8 SST NOTCH1 MEN1 GAST CHGA
9 lung benign neoplasm 30.7 SYP NKX2-1 ENO2 CHGA
10 pernicious anemia 30.7 SST GAST CHGA
11 pulmonary valve insufficiency 30.6 SST CHGA
12 somatostatinoma 30.6 SSTR2 SST MEN1 GAST ENO2 CHGA
13 small cell carcinoma 30.5 SYP NKX2-1 ENO2 CHGA
14 cystic teratoma 30.5 SYP NKX2-1 ENO2 CHGA
15 benign teratoma 30.5 SYP NKX2-1 ENO2 CHGA
16 carcinoid syndrome 30.5 SYP SST ENO2 CHGA
17 autoimmune gastritis 30.5 GAST CHGA
18 struma ovarii 30.4 SYP NKX2-1
19 atrophic gastritis 30.4 SST MEN1 GAST CHGA
20 lung oat cell carcinoma 30.3 SYP ENO2 CHGA
21 mediastinal cancer 30.3 SYP NKX2-1 ENO2 CHGA
22 zollinger-ellison syndrome 30.3 SST MEN1 GAST CHGA
23 neurofibromatosis, type i 30.3 SST MEN1 ENO2
24 obstructive jaundice 30.2 SYP SST
25 ectopic cushing syndrome 30.2 SYP SST CHGA
26 endocrine gland cancer 30.2 SYP SST GAST CHGA
27 tricuspid valve stenosis 30.1 SST CHGA
28 pulmonary sclerosing hemangioma 30.1 SYP NKX2-1 CHGA
29 secretory diarrhea 30.0 SST GAST
30 orbital cancer 30.0 SYP ENO2
31 sclerosing hemangioma 30.0 SYP NKX2-1 CHGA
32 tubular adenocarcinoma 30.0 SYP ENO2 CHGA
33 glomus tumor 30.0 SYP ENO2
34 neuroendocrine carcinoma 30.0 SYP SST NOTCH1 NKX2-1 MEN1 GAST
35 middle ear adenoma 30.0 SYP ENO2 CHGA
36 ampulla of vater benign neoplasm 30.0 SYP SST ENO2 CHGA
37 dumping syndrome 29.9 SST GAST
38 suppression of tumorigenicity 12 29.9 SYP ENO2 CHGA
39 sertoli-leydig cell tumor 29.9 SYP ENO2
40 peptic ulcer disease 29.9 SST MEN1 GAST
41 patent foramen ovale 29.9 SST NKX2-1 CHGA
42 pituitary adenoma 29.9 SSTR2 SST MEN1 CHGA
43 pituitary tumors 29.9 SST MEN1
44 malignant teratoma 29.9 SYP ENO2
45 acinar cell carcinoma 29.9 SYP GAST CHGA
46 hypoglycemia 29.8 SST GAST CHGA
47 pineocytoma 29.8 SYP ENO2 CHGA
48 jejunal neoplasm 29.8 SYP ENO2
49 mature teratoma of the ovary 29.8 SYP ENO2
50 ewing sarcoma 29.8 SYP ENO2 CHGA

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to Carcinoid Tumors, Intestinal

Symptoms & Phenotypes for Carcinoid Tumors, Intestinal

Human phenotypes related to Carcinoid Tumors, Intestinal:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intestinal carcinoid 30 HP:0006723

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Oncology:
intestinal carcinoid
appendiceal carcinoid
malignant carcinoid of ileum

Clinical features from OMIM®:

114900 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.61 CHGA CHGB ENO2 MEN1 NKX2-1 NOTCH1
2 digestive/alimentary MP:0005381 9.1 GAST MEN1 NKX2-1 NOTCH1 SST SSTR2

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 3 51-45-6 774
2
Cyproheptadine Approved Phase 3 129-03-3 2913
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
4
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
5
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 11947679 6857599
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 3-Iodobenzylguanidine Phase 3
9 Immunoglobulins, Intravenous Phase 3
10 Immunoglobulins Phase 3
11 Antibodies, Monoclonal Phase 3
12 Antibodies Phase 3
13 Mitogens Phase 3
14 Immunoglobulin G Phase 3
15 Endothelial Growth Factors Phase 3
16 Dermatologic Agents Phase 3
17 Gastrointestinal Agents Phase 3
18
Histamine phosphate Phase 3 51-74-1 134614
19 Anti-Allergic Agents Phase 3
20 Histamine H1 Antagonists Phase 3
21 Histamine Antagonists Phase 3
22 Angiogenesis Inhibitors Phase 2, Phase 3
23 Immunosuppressive Agents Phase 2, Phase 3
24 Vitamins Phase 2, Phase 3
25 Folate Phase 2, Phase 3
26 Vitamin B9 Phase 2, Phase 3
27 Trace Elements Phase 2, Phase 3
28 Vitamin B Complex Phase 2, Phase 3
29 Antidotes Phase 2, Phase 3
30 Micronutrients Phase 2, Phase 3
31 Protective Agents Phase 2, Phase 3
32 Hormone Antagonists Phase 3
33 Neurotransmitter Agents Phase 3
34 5-Hydroxytryptophan Phase 3
35 Serotonin Receptor Agonists Phase 3
36
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
37
Lactitol Approved, Investigational Phase 1, Phase 2 585-86-4 157355
38
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
41
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
42
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Lenograstim Approved, Investigational Phase 2 135968-09-1
45
Hydroxyurea Approved Phase 2 127-07-1 3657
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
47
Streptozocin Approved, Investigational Phase 2 18883-66-4, 66395-18-4 29327
48
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
49
Floxuridine Approved Phase 2 50-91-9 5790
50
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration. Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
2 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
5 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
6 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
7 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
8 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
9 A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. Completed NCT00690430 Phase 3 Pasireotide;Octreotide
10 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Completed NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
11 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
12 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
13 Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Not yet recruiting NCT04820751 Phase 3 Cyproheptadine Hydrochloride 4 MG
14 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
15 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
16 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
17 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Withdrawn NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
18 Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
19 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
20 A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
21 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
22 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
23 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
24 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
25 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
26 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
27 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
28 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
29 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
30 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
31 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
32 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
33 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
34 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
35 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
36 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
37 A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET). Completed NCT03722511 Phase 2
38 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
39 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
40 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
41 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
42 A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma Completed NCT00781911 Phase 2 depot octreotide
43 A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
44 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib
45 A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
46 Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
47 A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
48 An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
49 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
50 A Phase II Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b

Genetic Tests for Carcinoid Tumors, Intestinal

Anatomical Context for Carcinoid Tumors, Intestinal

Organs/tissues related to Carcinoid Tumors, Intestinal:

MalaCards : Small Intestine, Lung, Appendix, Heart, Liver, Thymus, Lymph Node

Publications for Carcinoid Tumors, Intestinal

Articles related to Carcinoid Tumors, Intestinal:

(show top 50) (show all 14730)
# Title Authors PMID Year
1
Complete maternal isodisomy of chromosome 8 in an individual with an early-onset ileal carcinoid tumor. 62 57
10925383 2000
2
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. 62 57
9361035 1997
3
Familial occurrence of metastasizing carcinoid tumors. 62 57
4694894 1973
4
A familial instance of appendiceal carcinoid. 62 57
5936207 1966
5
Prophylactic cholecystectomy in midgut carcinoid patients. 53 62
20130865 2010
6
PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. 53 62
20414099 2010
7
Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. 53 62
20075713 2010
8
Pure red-cell aplasia as the presenting feature of the carcionoid tumor of the thymus: case report. 53 62
19224408 2010
9
MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype. 53 62
19765735 2010
10
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. 53 62
19845567 2010
11
[Somatostatin receptor scintigraphy in pediatric bronchial carcinoid tumor]. 53 62
19819594 2010
12
Primary liver carcinoid tumour with a Zollinger Ellison syndrome - an unusual diagnosis: a case report. 53 62
19918579 2009
13
Primary ovarian carcinoid tumor with luteinized stromal cells. 53 62
19039598 2009
14
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature. 53 62
19523243 2009
15
Plasma chromogranin a in patients with inflammatory bowel disease. 53 62
19090560 2009
16
Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. 53 62
19065104 2009
17
Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. 53 62
19245907 2009
18
The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. 53 62
19337629 2009
19
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. 53 62
19030935 2009
20
Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. 53 62
19017754 2009
21
Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. 53 62
19047909 2009
22
Gastric-and-intestinal mixed endocrine cell phenotypic expression of carcinoid tumors in the rectum. 53 62
19082450 2009
23
Single brain metastasis from a minute, well differentiated, but invading beyond the tunica muscularis mucosa rectal carcinoid. 53 62
19402375 2009
24
Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. 53 62
18840995 2009
25
Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. 53 62
19149223 2008
26
Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. 53 62
19088697 2008
27
Metastatic atypical carcinoid tumor of the inferior rectus muscle. 53 62
19033849 2008
28
Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. 53 62
18719002 2008
29
Tachykinins in endocrine tumors and the carcinoid syndrome. 53 62
18524798 2008
30
Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. 53 62
18655788 2008
31
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. 53 62
18516757 2008
32
Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. 53 62
18430897 2008
33
Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. 53 62
18448176 2008
34
Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. 53 62
18535873 2008
35
Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. 53 62
18303072 2008
36
Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue. 53 62
18223557 2008
37
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. 53 62
17717663 2008
38
Germ cell origin of testicular carcinoid tumors. 53 62
18316560 2008
39
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 53 62
18323556 2008
40
Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. 53 62
18224665 2008
41
Multiple gastric carcinoids associated with parietal cell hyperplasia: intraoperative detection with a radiolabeled somatostatin analog. 53 62
18595020 2008
42
Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. 53 62
18172265 2008
43
[Somatostatin analogues in the treatment of carcinoid]. 53 62
18578378 2008
44
[Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up]. 53 62
18048114 2007
45
Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. 53 62
18049175 2007
46
Tailored intermittent therapy of carcinoid. 53 62
18019702 2007
47
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. 53 62
17766653 2007
48
Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. 53 62
17469181 2007
49
Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. 53 62
17578375 2007
50
Molecular targeted therapy for neuroendocrine tumors. 53 62
17548041 2007

Variations for Carcinoid Tumors, Intestinal

ClinVar genetic disease variations for Carcinoid Tumors, Intestinal:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SDHD NM_003002.4(SDHD):c.149A>G (p.His50Arg) SNV Uncertain Significance
6909 rs11214077 GRCh37: 11:111958677-111958677
GRCh38: 11:112087953-112087953

Expression for Carcinoid Tumors, Intestinal

Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.

Pathways for Carcinoid Tumors, Intestinal

Pathways related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 SYP NOTCH1 NKX2-1 ENO2

GO Terms for Carcinoid Tumors, Intestinal

Cellular components related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal dense core vesicle GO:0098992 8.8 SST CHGA

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell-substrate adhesion GO:0010812 9.26 NOTCH1 MEN1
2 forebrain development GO:0030900 9.1 SSTR2 NOTCH1 NKX2-1

Molecular functions related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 SST GAST CHGB

Sources for Carcinoid Tumors, Intestinal

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....